Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ADAM and Ephrin

Researchers target ADAM10 in lung fibrosis

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by the receptor tyrosine kinase ephrin B2.

ADAM metallopeptidase domain 10 (ADAM10) is a “sheddase,” whose role is to cleave membrane proteins and release soluble ectodomains that regulate

Read the full 610 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE